(Q30942279)

English

Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 June 2017

Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature (English)

1 reference

Europe PubMed Central

27 June 2017

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Georg A Bjarnason

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Bishoy Khalil

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

John M Hudson

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ross Williams

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mostafa Atri

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alex Kiss

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter N Burns

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2015

1 reference

Europe PubMed Central

27 June 2017

Urologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

171-178

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Improved flow measurement using microbubble contrast agents and disruption-replenishment: clinical application to tumour monitoring

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Sunitinib rechallenge in metastatic renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Hypertension as a predictive factor of Sunitinib activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Identifiers

10.1016/J.UROLONC.2015.03.003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30942279&oldid=1643591803"